0001415889-24-008771.txt : 20240320
0001415889-24-008771.hdr.sgml : 20240320
20240320180025
ACCESSION NUMBER: 0001415889-24-008771
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240318
FILED AS OF DATE: 20240320
DATE AS OF CHANGE: 20240320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gillies Hunter
CENTRAL INDEX KEY: 0001868997
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 24768833
MAIL ADDRESS:
STREET 1: C/O AEROVATE THERAPEUTICS, INC.
STREET 2: 200 BERKELEY STREET, FLOOR 18
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4-03202024_060312.xml
X0508
4
2024-03-18
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001868997
Gillies Hunter
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM
MA
02451
false
true
false
false
CHIEF MEDICAL OFFICER
1
Common Stock
2024-03-18
4
M
0
4000
1.74
A
7251
D
Common Stock
2024-03-18
4
M
0
3000
2.14
A
10251
D
Common Stock
2024-03-18
4
S
0
6387
25.8137
D
3864
D
Common Stock
2024-03-18
4
S
0
613
26.4022
D
3251
D
Stock Option (Right to Buy)
1.74
2024-03-18
4
M
0
4000
0
D
2030-09-03
Common Stock
4000
4036
D
Stock Option (Right to Buy)
2.14
2024-03-18
4
M
0
3000
0
D
2031-04-01
Common Stock
3000
98510
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.25 to $26.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.25 to $26.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments.
/s/ George A. Eldridge, Attorney-in-Fact
2024-03-20